FindTrial
Sign In

Effect differences of conventional and newer atypical antipsychotics – Perphenazine and brain dopamine D2 receptor blockade

Effect differences of conventional and newer atypical antipsychotics – Perphenazine and brain dopamine D2 receptor blockade

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2007-004062-41-FI
Enrollment
Unknown
Registered
2007-07-19
Start date
2007-08-13
Completion date
Unknown
Last updated
2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Tutkittavat ovat terveitä.

Interventions

Trade Name: Peratsin Pharmaceutical Form: INN or Proposed INN: PERPHENAZINE CAS Number: 58399 Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use

Sponsors

Jarmo Hietala
Lead Sponsor

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Main Objective: ;Secondary Objective: ;Primary end point(s):—

Countries

Finland

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026